Highlights

  • CSL Ltd (ASX:CSL) has fallen 44.93% over the past six months despite posting AUD15.55 bn in Revenue and USD3.00 bn in net profit.
  • CSL revised down its FY26 outlook following weaker-than-expected revenue contributions across several Business segments.
  • Broker consensus data currently shows an overall Buy recommendation with a target price of AUD147.62.
  • CSL expects approximately USD5 bn in additional non-cash pre-tax impairments across FY26 and FY27.
  • The stock trades near the lower end of its 52-week range of AUD93.64 to AUD275.79.

CSL Limited (ASX:CSL) has returned to market focus after one of the sharpest corrections seen among large-cap ASX healthcare stocks over recent months. After trading well above AUD275 within the past year, the company’s shares closed at AUD98.69 on 19 May 2026, placing the stock near its 52-week low of AUD93.64.

The scale of the decline has become a key discussion point for investors. CSL shares are down 1.51% over the past five trading sessions, have declined 28.18% over the past month, and are lower by 44.93% over the past six months. Despite the recent pressure, the stock rose 2.57% in the latest Trading session.

The move has coincided with changes to the company’s FY26 outlook, additional Impairment expectations, and ongoing Leadership transition developments.

Revised FY26 Guidance Reshapes Sentiment

CSL recently updated the market on its FY26 expectations, stating that revenue is now expected to be around USD15.2 bn, while NPATA excluding restructuring costs and impairments is projected at approximately USD3.1 bn on a constant currency basis.

Interim Chief Executive Officer and Managing Director Gordon Naylor said the company had completed a detailed business review after he assumed the interim leadership role in February.

According to CSL, several operational factors contributed to the revised outlook. The company highlighted the normalisation of channel inventory in U.S. Immunoglobulin, which is expected to create an approximately USD300 mn revenue impact. In China, CSL stated that albumin Market Value declined despite stabilising volumes and expanding Market Share, creating an expected revenue impact of around USD200 mn.

The company also cited the impact of Middle East conflict conditions, revised HEMGENIX growth expectations, and increased competition in iron products as contributing factors to an additional estimated USD150 mn revenue impact.

Growth Initiatives Continue Across Operations

While the guidance downgrade affected market sentiment, CSL stated that several transformation and operational initiatives remain underway.

The company said it is progressing portfolio and commercial execution initiatives, with early indicators suggesting improvement in end-patient Demand and momentum across recent product launches.

CSL also pointed to operational simplification measures designed to reduce complexity and improve cost efficiency across the business. Transformation initiatives and cost reduction programs are also continuing according to plan.

The company further stated that CSL Seqirus’ FY26 financial performance is expected to be moderately better than previously anticipated, while CSL Behring is still expected to deliver second-half revenue growth supported by underlying demand and operational initiatives.

Impairments Add Another Layer Of Pressure

Another major development weighing on sentiment is CSL’s expectation that it will recognise approximately USD5 bn in additional non-cash pre-tax impairments across FY26 and FY27.

The impairments are linked to CSL Vifor intangible assets, including parts of the product portfolio, as well as under-utilised property, plant and equipment.

CSL noted that the impairments remain subject to further analysis, external audit processes, business developments, and Board approval ahead of the company’s FY26 full-year results.

The announcement added further uncertainty to a stock already undergoing a substantial re-rating in the market.

Broker Consensus Still Reflects Buy Recommendation

Despite the steep share price correction, broker consensus data continues to indicate a Buy recommendation on CSL shares.

Consensus estimates currently show a recommendation score of 2.44 with a target price of AUD147.62, implying upside relative to the latest traded price. The consensus data also showed multiple analyst recommendations ranging from Buy and Outperform to Hold.

The contrast between the declining share price and the standing broker recommendations has become a central focus for investors assessing whether the recent correction reflects changing fundamentals or a broader market reassessment of future Earnings expectations.

Financial Position And Dividend Snapshot

CSL reported revenue of USD15.55 bn and net profit of USD3.00 bn in its latest financial figures. The company currently carries a Market Capitalisation of AUD46.08 bn and trades on a price-to-earnings ratio of 23.95.

The stock also reported a free Cash Flow Yield of 7.28% and an Annual Dividend Yield of 4.42%. CSL recently declared an Interim Dividend of USD1.300 per share, with payment completed in April 2026.

Trading activity remains elevated, with daily Volume reaching more than 1.37 million shares in the latest session.